Study of receptors involved in anticancer therapy

dc.contributor.authorMUSTAFA FADHIL, Swaleh Said
dc.contributor.authorMARIAM, Ahmed Mohamed
dc.date.accessioned2026-05-04T11:58:31Z
dc.date.available2026-05-04T11:58:31Z
dc.date.issued2025-07-10
dc.description.abstractBackground: PD-L1(Programmed Death Ligand-1) is a key immune checkpoint target in anticancer therapy. Many small molecule inhibitors have been proposed via in silico studies, but their comparative performance analysis remains lacking. Objective: To conduct a meta-analysis of PD-L1 inhibitors based on binding affinities, interaction patterns and structural features. Methods: Data from 27 articles covering 69 ligands were analyzed. Variables included binding free energies, RMSD values, molecular interactions and key amino acids. A forest plot was constructed to statistically evaluate binding affinity variations. Results: The forest plot showed a statistically significant difference in binding energies (Z= 6.09, p< 0.00001), confirming non-random performance among top ligands. Common residues included Tyr56, Met115 and Ala121. Frequent features were hydrogen bonds, π-π stacking and hydrophobic interactions. Conclusion: This work identifies key interaction motifs and substituents for potent PD-L1 inhibition, supporting their use in future structure-based drug design.
dc.identifier.urihttps://dspace.univ-tlemcen.dz/handle/112/26122
dc.language.isoen
dc.publisherUniversity of Tlemcenen_US
dc.titleStudy of receptors involved in anticancer therapy
dc.typeThesis

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Study-of-Receptors-Involved-in-Anticancer-Therapy.pdf
Size:
3.44 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: